Pharmacokinetic/pharmacodynamic analysis of high-dose tigecycline, by Monte Carlo simulation, in plasma and sputum of patients with hospital-acquired pneumonia.
Xiaohong QinLingti KongChenchen WuXiaohua ZhangMeng XieXiaofei WuPublished in: Journal of clinical pharmacy and therapeutics (2022)
In this study, we explored PK/PD of high-dose tigecycline in plasma and sputum. From a PK/PD perspective, high-dose tigecycline had greater therapeutic outcomes in HAP treatment caused by MDRB. Antimicrobial-drug concentrations should be determined to optimize their clinical use.
Keyphrases
- high dose
- acinetobacter baumannii
- monte carlo
- stem cell transplantation
- low dose
- klebsiella pneumoniae
- cystic fibrosis
- mycobacterium tuberculosis
- pulmonary tuberculosis
- multidrug resistant
- pseudomonas aeruginosa
- drug resistant
- staphylococcus aureus
- adverse drug
- type diabetes
- weight loss
- acute care
- insulin resistance
- drug induced
- extracorporeal membrane oxygenation
- smoking cessation